检索结果-南通市图书馆

Considering the cost-effectiveness of statins in family practice in Turkey from a payer perspective

Health 2009年第4期1卷 274-280页

作者： Güvenc kockaya Albert Wertheimer pinar daylan kockaya Ahmet Esen Yeditepe Universitesi PEPI IstanbulTurkey Temple University School of PharmacyPhiladelphiaUSA Sisli Etfal Education and Research Hospital Anesthesia ClinicIstanbulTurkey

The percentage of mortality caused by cardio-vascular events in European Countries and European Union Countries is respectively 49% and 42% of all mortality causes. Our estimates about cardiovascular mortality in Turkey depend on TEKHARF (Hearth Disease and Risk Factors in Turkish Adults) which depended on a 12 year observation. It has been reported that cardio-vascular mortality rates for Turkey in men and women were 0.082% and 0.043% respectively. In Turkey, Atorvastatin, Fluvastatin, Pravastatin, Rosuvastatin and Simvastatin are the different alternatives found in the statin market. All stat-ins are reimbursed by insurance companies. The aim of this study is to determine the cost- effectiveness of statins. In conclusion, simvas-tatin and rosuvastatin comprised the optimal two statin alternatives.

关键词： Hypercholesterolemia Cardiovascular Disease Cost-Effectiveness Analysis Decision Analysis Mode

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Economic Impact of Clinical Research to Research Centers and Opportunity Cost for the Reimbursement System in Turkey

引用

Health 2015年第9期7卷 1124-1133页

作者： Güvenc kockaya Meral Demir pinar daylan kockaya Mehtap Tatar Ali Yagizüresin Istanbul University IstanbulTurkey Ministry of Health AnkaraTurkey Hacettepe University AnkaraTurkey

Introduction: Clinical research is a key component of drug development with a significant economic value. It has been reported that the development of a new molecule requires 10 - 15 years and costs almost $1.3 billion. Around 75% of the cost is spent on the Phase I-IV clinical research process. This study aimed to show the economic value of clinical research in Turkey. Methods: Clinical trial budgets were estimated from the raw data of the Report of Istanbul Medical Faculty Clinical Research (ITFKAR). In the research, the estimated cost of drugs used in the clinical trials for the Turkish reimbursement agency (SGK) was calculated to show the cost of medicines acquired through clinical research. Results: The total budget for sponsored pharmaceutical research was $107 million in Turkey, and the government saved close to $311,096,130 during 2006-2010, due to not reimbursing the patients for the drugs in the clinical trials. Conclusion: Despite the limitations of the study, the findings are unique for Turkey. The results can lead to revisiting the importance and economic value of clinical trials in Turkey.

关键词： Clinical Research Economic Impact Reimbursement Research Centers Opportunity Cost

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：